Forty Seven Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Forty Seven Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2810
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is evaluated in four phase 1 clinical studies in patients with solid tumors or cutaneous T-cell lymphoma, acute myeloid leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndrome and colorectal carcinoma across the US and the UK. The company partners with biotechnology and pharmaceutical companies. Forty Seven is headquartered in Menlo Park, California, the US.

Forty Seven Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Forty Seven Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Forty Seven Raises USD75 Million in Series B Financing 11
Forty Seven Raises USD75 Million in Series A Venture Financing 12
Partnerships 13
Forty Seven Enters into Agreement with Merck 13
Forty Seven Enters into Agreement with Genentech 14
Licensing Agreements 15
Forty Seven Enters into Licensing Agreement with Stanford University 15
Equity Offering 16
Forty Seven Prices IPO of Shares for USD112.5 Million 16
Forty Seven Inc – Key Competitors 18
Forty Seven Inc – Key Employees 19
Forty Seven Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Apr 30, 2018: Forty Seven Names Ian T. Clark As Board Director 21
Apr 03, 2018: Forty Seven Appoints Ann D. Rhoads as Chief Financial Officer 22
Feb 20, 2018: Forty Seven Appoints Kristine M. Ball to Board of Directors 23
Mar 20, 2017: Forty Seven Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st 24
Product News 25
12/06/2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia 25
04/05/2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Forty Seven Inc, Pharmaceuticals & Healthcare, Key Facts 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Forty Seven Raises USD75 Million in Series B Financing 11
Forty Seven Raises USD75 Million in Series A Venture Financing 12
Forty Seven Enters into Agreement with Merck 13
Forty Seven Enters into Agreement with Genentech 14
Forty Seven Enters into Licensing Agreement with Stanford University 15
Forty Seven Prices IPO of Shares for USD112.5 Million 16
Forty Seven Inc, Key Competitors 18
Forty Seven Inc, Key Employees 19

List of Figures
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forty Seven Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forty Seven Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Forty Seven Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Catalyst Paper Corp:企業の戦略的SWOT分析
    Catalyst Paper Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Air Liquide SA (AI):企業の財務・戦略的SWOT分析
    Air Liquide SA (AI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Covalon Technologies Ltd (COV)-製薬・医療分野:企業M&A・提携分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen …
  • Huntsman Corp (HUN):企業の財務・戦略的SWOT分析
    Huntsman Corp (HUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Centrais Eletricas Brasileiras S.A. (ELET6):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas Brasileiras S.A. (Eletrobras) is an electric utility. It generates, transmits, and distributes energy. The company produces electricity from hydro, nuclear, wind, natural gas, oil, coal, solar, and biomass sources. Eletrobras promotes the Latin American electric integratio …
  • Fortum Corporation:企業の戦略・SWOT・財務情報
    Fortum Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Oglethorpe Power Corporation:企業の戦略・SWOT・財務分析
    Oglethorpe Power Corporation - Strategy, SWOT and Corporate Finance Report Summary Oglethorpe Power Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • SOCO International plc (SIA):企業の財務・戦略的SWOT分析
    Summary SOCO International Plc (SOCO) is an oil and gas company that explores, discovers and produces oil and gas reserves. The company offers appraisal and field development services. It provides training and skills and support local communities. SOCO produces and supplies natural resources. SOCO h …
  • Autotelic Inc-製薬・医療分野:企業M&A・提携分析
    Summary Autotelic Inc (Autotelic) is a therapeutic drug monitoring company that develops novel treatments using its therapeutic drug monitoring (TDM) services. The company's pipeline products includes devices to improve safety and efficacy of COX-2 inhibitors, paclitaxel nanomedicine and TGF-beta in …
  • Dis-Chem Pharmacies Limited (DCP):企業の財務・戦略的SWOT分析
    Dis-Chem Pharmacies Limited (DCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Suzuki Motor Corporation (7269):企業の財務・戦略的SWOT分析
    Suzuki Motor Corporation (7269) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Spine Injury Solutions Inc (SPIN):企業の財務・戦略的SWOT分析
    Summary Spine Injury Solutions Inc (SPIN), formerly Spine Pain Management Inc is a medical service provider that provides medical technology and healthcare management solutions for liability spine injuries. The company provides services such as clinical management, and billing and collection of medi …
  • EIH Limited:戦略・SWOT・企業財務分析
    EIH Limited - Strategy, SWOT and Corporate Finance Report Summary EIH Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • GlySens Inc:医療機器:M&Aディール及び事業提携情報
    Summary GlySens Inc (GlySens) is a medical device company that offers glucose monitoring systems. The company develops GlySens ICGM system, a fully-implanted continuous glucose monitoring system intended to improve the lives of people with diabetes. GlySens offers continuous glucose sensor, which ha …
  • Nichi-Iko Pharmaceutical Co Ltd (4541):企業の財務・戦略的SWOT分析
    Summary Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic products. The company eripheral nervous system medicines. The company offers products such as alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium sulfate, betahis …
  • WEC Energy Group:企業の戦略・SWOT・財務情報
    WEC Energy Group - Strategy, SWOT and Corporate Finance Report Summary WEC Energy Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alimera Sciences Inc (ALIM):医療機器:M&Aディール及び事業提携情報
    Summary Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabet …
  • Butler National Corporation:企業の戦略・SWOT・財務情報
    Butler National Corporation - Strategy, SWOT and Corporate Finance Report Summary Butler National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Porsche Automobil Holding SE (PAH3):企業の財務・戦略的SWOT分析
    Porsche Automobil Holding SE (PAH3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Kiewit Corp:企業の戦略的SWOT分析
    Kiewit Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆